Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Ltd. today announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion.
from The Medical News http://ift.tt/17p7ODe
from The Medical News http://ift.tt/17p7ODe
No comments:
Post a Comment